Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29195613 | 0.85 | ALDH1A1 (0.62) | ALDH1A1LMNASLC15A2TSHRTDP1 | |
| SCHEMBL339534 | 0.85 | ALDH1A1 (0.62) | ALDH1A1LMNASLC15A2TSHRTDP1 | |
| SCHEMBL118947 | 0.84 | ALDH1A1 (0.50) | ALDH1A1TSHR | |
| SCHEMBL28289780 | 0.83 | ALDH1A1 (0.59) | ALDH1A1LMNASLC15A2TSHRTDP1 | |
| SCHEMBL233404 | 0.82 | ALDH1A1 (0.68) | ALDH1A1LMNATSHR | |
| SCHEMBL27566761 | 0.81 | ALDH1A1 (0.50) | ALDH1A1LMNASLC15A2TSHRTDP1 | |
| SCHEMBL562036 | 0.79 | ALDH1A1 (0.41) | ALDH1A1TSHRTDP1 | |
| SCHEMBL43574 | 0.79 | EGLN1 (0.43) | ALDH1A1LMNASLC15A2TSHR | |
| SCHEMBL6526444 | 0.78 | ALDH1A1 (0.50) | ALDH1A1LMNATSHRMAPT | |
| Ethylene Glycol SCHEMBL18076243 | 0.78 | ALDH1A1 (0.44) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46171-E1 | Functional biopolymer modification reagents and uses thereof | SOLULINK, INCORPORATED (US) | 2016-10-04 | — | — | US | disclosed |
| US-7732628-B2 | Such as 4-[8-(2-cyanoethyl-N,N-diisopropylphosphoramidyloxy)-2-aza-1-oxooct-1-yl]benzaldehyde, 4-[8-(2-cyanoethyl-N,N-diisopropylphosphoramidyloxy)-2-aza-1-oxooct-1-yl]acetophenone; for incorporation into oligonucleotides during immobilization and conjugation of biopolymers in solid phase synthesis | SOLULINK INCORPORATED (US) | 2010-06-08 | — | — | US | disclosed |
| US-20070179288-A1 | Triphosphate oligonucleotide modification reagents and uses thereof | AUDAX PRIVATE DEBT LLC, AS AGENT | 2007-08-02 | — | — | US | disclosed |
| US-7173125-B2 | Triphosphate oligonucleotide modification reagents and uses thereof | AUDAX PRIVATE DEBT LLC, AS AGENT | 2007-02-06 | — | — | US | disclosed |
| US-7102024-B1 | Functional biopolymer modification reagents and uses thereof | AUDAX PRIVATE DEBT LLC, AS AGENT | 2006-09-05 | — | — | US | disclosed |
| US-20050266427-A1 | Biomolecule/polymer conjugates | SOLULINK BIOSCIENCES, INC. | 2005-12-01 | — | — | US | disclosed |
| US-20050203289-A1 | Functional biopolymer modification reagents and uses thereof | AUDAX PRIVATE DEBT LLC, AS AGENT | 2005-09-15 | — | — | US | disclosed |
| US-6911535-B2 | Covalently linking natural or synthetic biomolecule to a mono-or bi-functional polymer; covalently and/or electrostatically immobilizing biomolecule/polymer conjugate to a unmodified or modified surface | SOLVLINK BIOSCIENCES (US) | 2005-06-28 | — | — | US | disclosed |
| EP-1351991-A4 | TERNARY BIOMOLECULE/POLYMER/SURFACE-BASED IMMOBILIZATION SYSTEMS | SCHWARTZ DAVID A (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040235027-A1 | Preparation and application of ligand-biopolymer conjugates | REGENT OF THE UNIVERSITY OF CALIFORNIA | 2004-11-25 | — | — | US | disclosed |
| US-20040214199-A1 | Triphosphate oligonucleotide modification reagents and uses thereof | AUDAX PRIVATE DEBT LLC, AS AGENT | 2004-10-28 | — | — | US | disclosed |
| WO-2004087865-A2 | THE PREPARATION AND APPLICATION OF LIGAND-BIOPOLYMER CONJUGATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-10-14 | — | — | WO | disclosed |
| US-6686461-B1 | HYDRAZINO, OXYAMINO AND CARBONYL-BASED MONOMERS AND METHODS FOR LABELLING OF OLIGONUCLEOTIDES WITHOUT THE NEED FOR POST-SYNTHETIC MODIFICATION | SOLULINK BIOSCIENCE, INC. | 2004-02-03 | — | — | US | disclosed |
| EP-1351991-A2 | TERNARY BIOMOLECULE/POLYMER/SURFACE-BASED IMMOBILIZATION SYSTEMS | Schwartz, David A. (US) | 2003-10-15 | — | — | EP | disclosed |
| EP-1305327-A2 | TRIPHOSPHATE OLIGONUCLEOTIDE MODIFICATION REAGENTS AND USES THEREOF | Schwartz, David A. (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20020146504-A1 | Ternary biomolecule/polymer/surface-based immobilization systems | AUDAX PRIVATE DEBT LLC, AS AGENT | 2002-10-10 | — | — | US | disclosed |
| WO-2002057422-A2 | TERNARY BIOMOLECULE/POLYMER/SURFACE-BASED IMMOBILIZATION SYSTEMS | SCHWARTZ DAVID A (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002010432-A2 | TRIPHOSPHATE OLIGONUCLEOTIDE MODIFICATION REAGENTS AND USES THEREOF | SCHWARTZ DAVID A (US) | 2002-02-07 | — | — | WO | disclosed |
| WO-2002010431-A2 | FUNCTIONAL BIOPOLYMER MODIFICATION REAGENTS AND USES THEREOF | SCHWARTZ DAVID A (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203289-A1 | Functional biopolymer modification reagents and uses thereof | OGG1, OGA, HMOX2 | ALDH1A1 360/4885LMNA 2943/4885SLC15A2 4267/4885 |
| US-20020146504-A1 | Ternary biomolecule/polymer/surface-based immobilization systems | EPCAM, DNPEP, ANPEP | ALDH1A1 552/4885LMNA 2752/4885SLC15A2 1671/4885 |
| US-20040214199-A1 | Triphosphate oligonucleotide modification reagents and uses thereof | RNGTT, DUT, NUDT1 | ALDH1A1 410/4885LMNA 2360/4885SLC15A2 4055/4885 |
| US-20070179288-A1 | Triphosphate oligonucleotide modification reagents and uses thereof | RNGTT, DUT, NUDT1 | ALDH1A1 412/4885LMNA 2257/4885SLC15A2 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.